Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications

This publication has 53 references indexed in Scilit:

• Co-expression of steroid hormone receptors (estrogen receptor α and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: Clinical outcome following tamoxifen-based adjuvant therapy
  The Journal of Steroid Biochemistry and Molecular Biology, 2005
• Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab
  Breast Cancer Research and Treatment, 2005
• Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
  Clinical Cancer Research, 2005
• Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer
  Annals of Oncology, 2005
• Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance
  Breast Cancer Research and Treatment, 2005
• Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy
  The Journal of Steroid Biochemistry and Molecular Biology, 2005
• Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status
  European Journal Of Cancer, 2004
• Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy
  Cell Research, 2004
• Estrogen receptors, progesterone receptors, and cell proliferation in human breast cancer
  Breast Cancer Research and Treatment, 1996
• A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors
  New England Journal of Medicine, 1989